Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001965621-24-000004
Filing Date
2024-11-26
Accepted
2024-11-26 16:48:29
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 3811
2 TRANSFER TO IRREV TRUST EX1.pdf EX-1 120864
3 FILING AND EX-99CERT Filing.pdf EX-99.CERT 171580
  Complete submission text file 0001965621-24-000004.txt   408534
Mailing Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731
Business Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731 512-501-2444
CASSAVA SCIENCES INC (Subject) CIK: 0001069530 (see all company filings)

EIN.: 911911336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-59335 | Film No.: 241504857
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 116 ADALIA AVENUE TAMPA FL 33606
Business Address
Nachtrab Matthew (Filed by) CIK: 0001965621 (see all company filings)

Type: SCHEDULE 13G/A